samedan logo
 
 
 
spacer
home > ebr > spring 2018 > getting ahead
PUBLICATIONS
European Biopharmaceutical Review

Getting Ahead

Migraine is not a new or a rare disease: references to migrainelike conditions can be found as far back as Ancient Egypt, and it has been recognised by the WHO as one of the top 10 causes of years lost to disability worldwide (1-2). Despite this, migraine patients in need of a preventive option are likely to be prescribed a medication that has been developed for another condition such as epilepsy or depression, rather than something that was designed with migraine in mind. However, there is hope that this will soon change.

Pathophysiology of Migraine

The understanding of the pathophysiology of migraine has advanced hugely over the past two decades. While in the past theories of migraine focused on the vascular system, research has moved away from this towards a neuronal theory of migraine (3). However, the role of blood vessels and vasodilation is still not entirely understood.

Migraine is a complex neurological disease of the central nervous system (CNS), with several structures and brain areas implicated in its genesis. A key focus area has been the trigeminovascular system. This has connections with other key brain areas with axons reaching as far as the meninges. Activation of this system is thought to be a crucial step in a chain of events leading to migraine pain.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Dr Uwe Reuter is a neurologist and partner in the headache programme at Charité Universitätsmedizin, Berlin. After finishing his residency training in Berlin, he went to Harvard Medical School for a post-doctorate fellowship as a scholar for three years. During his time in Boston, Uwe focused on basic research in primary headaches and migraine aura and published several peer-reviewed publications in high impact journals. Ever since, he has had a strong interest in basic and clinical headache research. Uwe is a member of several national and international headache organisations and currently serves as board member of the European Headache Federation.
spacer
Professor Dr Uwe Reuter
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New laboratory and regulatory services for biotech customers

USA/Germany, September 21, 2020. Gerresheimer adds essential laboratory and regulatory services to its broad portfolio of products, solutions and services for biotech companies. Specialized laboratory technicians and an experienced team of further specialists offer these services in the two innovation and technology centers in Bünde (Germany) and Vineland (New Jersey/USA). Gx Biological Solutions offers full service for biotech companies regarding product development of primary packaging and drug delivery solutions, material and functional testing as well as comprehensive regulatory support. The partnership with Gerresheimer shortens the time to market for pharmaceutical companies, minimizes risks and saves resources.
More info >>

White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement